Fintech industry stories

Sep 25, 2026

Novo Nordisk signs $1.3 billion deal with Nanexa for long-acting drug delivery technology

Novo Nordisk agreed to pay up to €1.165 billion ($1.3 billion) for a global license to Swedish biotech Nanexa's PharmaShell drug delivery technology, which could enable obesity medications requiring injections only once every few months. Nanexa shares surged more than 110% on the announcement.

Sep 25, 20265 sources

Sep 3, 2026

Ultragenyx's Angelman syndrome drug fails Phase 3 trial

Ultragenyx Pharmaceuticals' apazunersen did not meet the goals of its Phase 3 test in Angelman syndrome, a rare genetic neurological disorder with no FDA-approved therapies. The failure of what was once considered a potential blockbuster therapy is forcing Ultragenyx to examine significant cost cuts.

Sep 3, 20262 sources

Top claims

▪Swedish drug-delivery company Nanexa AB announced a global licensing and collaboration agreement with Novo Nordisk A/S on Thursday, 24 September 2026.
▪The agreement provides for Nanexa AB to receive low-single-digit royalties on global net sales of any products emerging from the partnership with Novo Nordisk A/S.
▪Nanexa AB is eligible to receive up to €615 million in upfront payments and development and regulatory milestones from Novo Nordisk A/S.

Subtopics

Drug Approval and Clinical Trials2 Drug Policy, Pricing & Approval2 Angelman syndrome1 Clinical evaluation1 Clinical Trial Design & Evaluation1 Clinical trials1 Drug approval process1 Drug Classes & Treatment Access1 Neurological disorders1 Pharma1

Related timelines